BCG — old workhorse, new skills

M. Gengenbacher; N. E. Nieuwenhuizen; S. H.E. Kaufmann

doi:10.1016/j.coi.2017.06.007

BCG — old workhorse, new skills

M. Gengenbacher
, N. E. Nieuwenhuizen
, S. H.E. Kaufmann

Center for Discovery and Innovation

Max Planck Institute for Infection Biology

Research output: Contribution to journal › Review article › peer-review

32 Scopus citations

Abstract

Bacille Calmette-Guérin (BCG), the only tuberculosis (TB) vaccine in clinical practice, has limitations in efficacy, immunogenicity and safety. Much current TB vaccine research focuses on engineering live mycobacteria to interfere with phagosome biology and host intracellular pathways including apoptosis and autophagy, with candidates such as BCG Δzmp1, BCG ΔureC::hly, BCG::ESX-1^Mmar, Mtb ΔphoP ΔfadD26, Mtb ΔRD1 ΔpanCD and M. smegmatis Δesx-3::esx-3(Mtb) in the development pipeline. Correlates of protection in preclinical studies include increased central memory CD4⁺ T cells and recruitment of antigen-specific T cells to the lungs, with mucosal vaccination found to be superior to parenteral vaccination. Finally, recent studies suggest beneficial non-specific effects of BCG on immunity, which should be taken into account when considering these vaccines for BCG replacement.

Original language	English
Pages (from-to)	8-16
Number of pages	9
Journal	Current Opinion in Immunology
Volume	47
DOIs	https://doi.org/10.1016/j.coi.2017.06.007
State	Published - Aug 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.coi.2017.06.007

Cite this

@article{54009cf3685446b0aad09a5a548e122d,

title = "BCG {\textemdash} old workhorse, new skills",

abstract = "Bacille Calmette-Gu{\'e}rin (BCG), the only tuberculosis (TB) vaccine in clinical practice, has limitations in efficacy, immunogenicity and safety. Much current TB vaccine research focuses on engineering live mycobacteria to interfere with phagosome biology and host intracellular pathways including apoptosis and autophagy, with candidates such as BCG Δzmp1, BCG ΔureC::hly, BCG::ESX-1Mmar, Mtb ΔphoP ΔfadD26, Mtb ΔRD1 ΔpanCD and M. smegmatis Δesx-3::esx-3(Mtb) in the development pipeline. Correlates of protection in preclinical studies include increased central memory CD4+ T cells and recruitment of antigen-specific T cells to the lungs, with mucosal vaccination found to be superior to parenteral vaccination. Finally, recent studies suggest beneficial non-specific effects of BCG on immunity, which should be taken into account when considering these vaccines for BCG replacement.",

author = "M. Gengenbacher and Nieuwenhuizen, \{N. E.\} and Kaufmann, \{S. H.E.\}",

note = "Publisher Copyright: {\textcopyright} 2017 The Authors",

year = "2017",

month = aug,

doi = "10.1016/j.coi.2017.06.007",

language = "English",

volume = "47",

pages = "8--16",

journal = "Current Opinion in Immunology",

issn = "0952-7915",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - BCG — old workhorse, new skills

AU - Gengenbacher, M.

AU - Nieuwenhuizen, N. E.

AU - Kaufmann, S. H.E.

PY - 2017/8

Y1 - 2017/8

N2 - Bacille Calmette-Guérin (BCG), the only tuberculosis (TB) vaccine in clinical practice, has limitations in efficacy, immunogenicity and safety. Much current TB vaccine research focuses on engineering live mycobacteria to interfere with phagosome biology and host intracellular pathways including apoptosis and autophagy, with candidates such as BCG Δzmp1, BCG ΔureC::hly, BCG::ESX-1Mmar, Mtb ΔphoP ΔfadD26, Mtb ΔRD1 ΔpanCD and M. smegmatis Δesx-3::esx-3(Mtb) in the development pipeline. Correlates of protection in preclinical studies include increased central memory CD4+ T cells and recruitment of antigen-specific T cells to the lungs, with mucosal vaccination found to be superior to parenteral vaccination. Finally, recent studies suggest beneficial non-specific effects of BCG on immunity, which should be taken into account when considering these vaccines for BCG replacement.

AB - Bacille Calmette-Guérin (BCG), the only tuberculosis (TB) vaccine in clinical practice, has limitations in efficacy, immunogenicity and safety. Much current TB vaccine research focuses on engineering live mycobacteria to interfere with phagosome biology and host intracellular pathways including apoptosis and autophagy, with candidates such as BCG Δzmp1, BCG ΔureC::hly, BCG::ESX-1Mmar, Mtb ΔphoP ΔfadD26, Mtb ΔRD1 ΔpanCD and M. smegmatis Δesx-3::esx-3(Mtb) in the development pipeline. Correlates of protection in preclinical studies include increased central memory CD4+ T cells and recruitment of antigen-specific T cells to the lungs, with mucosal vaccination found to be superior to parenteral vaccination. Finally, recent studies suggest beneficial non-specific effects of BCG on immunity, which should be taken into account when considering these vaccines for BCG replacement.

UR - https://www.scopus.com/pages/publications/85024101364

U2 - 10.1016/j.coi.2017.06.007

DO - 10.1016/j.coi.2017.06.007

M3 - Review article

C2 - 28719821

AN - SCOPUS:85024101364

SN - 0952-7915

VL - 47

SP - 8

EP - 16

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

ER -

BCG — old workhorse, new skills

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this